Standout Papers

Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves ... 2005 2026 2012 2019 694
  1. Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer (2005)
    Fairooz F. Kabbinavar, Julie Hambleton et al. Journal of Clinical Oncology
  2. Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial (2005)
    Fairooz F. Kabbinavar, Joseph J. Schulz et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 21 from Science/Nature 72 standout
Sub-graph 1 of 19

Citing Papers

The biology and management of non-small cell lung cancer
2018 StandoutNature
Personalized medicine: Time for one-person trials
2015 StandoutNature
3 intermediate papers

Works of R. Mass being referenced

TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
2004
The role of HER-2 expression in predicting response to therapy in breast cancer.
2000
and 1 more

Author Peers

Author Last Decade Papers Cites
R. Mass 2431 1177 585 1007 43 3.4k
Scott N. Holden 2208 849 810 1300 42 3.6k
Jacques Gaudreault 1336 1173 678 1167 36 3.2k
Peter Langmuir 1811 1620 262 1289 55 4.6k
Frank A. Scappaticci 1382 842 202 1193 38 2.8k
Jana Prausová 3323 1445 291 671 52 4.0k
Peter Vermeulen 2257 753 299 1383 76 3.9k
Timothy G. Cooke 1881 399 982 1171 64 3.4k
Henry Q. Xiong 2812 1285 269 1195 39 4.3k
Robert Lim 3023 1359 331 1329 52 4.4k
Dana D. Hu‐Lowe 997 788 338 1734 33 3.0k

All Works

Loading papers...

Rankless by CCL
2026